Incidence and consequences of bone metastases in lung cancer patients

被引:75
作者
Kuchuk, Michael [1 ,2 ]
Addison, Christina L. [3 ,4 ,5 ]
Clemons, Mark [1 ,2 ,3 ]
Kuchuk, Iryna [1 ,2 ]
Wheatley-Price, Paul [1 ,2 ]
机构
[1] Univ Ottawa, Div Med Oncol, Ottawa, ON, Canada
[2] Ottawa Hosp Canc Ctr, Ottawa, ON K1H 8L6, Canada
[3] Ottawa Hosp Res Inst, Program Canc Therapeut, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Med & Biochem, Ottawa, ON, Canada
[5] Univ Ottawa, Dept Microbiol & Immunol, Ottawa, ON, Canada
关键词
Non-small cell lung cancer; Bone metastasis; Skeletal related event; Bisphosphonates and denosumab; SKELETAL-RELATED EVENTS; LONG-TERM EFFICACY; ZOLEDRONIC ACID; DOUBLE-BLIND; BREAST-CANCER; PALLIATIVE RADIOTHERAPY; 1ST-LINE TREATMENT; PROSTATE-CANCER; SOLID TUMORS; OPEN-LABEL;
D O I
10.1016/j.jbo.2012.12.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Bone metastases (BM) are common in NSCLC patients. Despite some potential positive effects of bone-targeted therapies, their use in NSCLC is infrequent, which may relate to the overall poor prognosis of advanced lung cancer. We reviewed the literature to evaluate the incidence, consequences and use of bone-targeting agents in lung cancer patients with BM in both the trial and non-trial clinical setting. Methods: Published prospective and retrospective papers investigating lung cancer and BM, in trial and non-trial settings, were identified and are discussed in this review. Results: BM are common in patients with advanced lung cancer and often present symptomatically with pain and skeletal related events (SREs). Patients with high bone turnover marker levels, multiple BM, and history of pathological fractures have shorter overall survival. In randomized studies bone-targeted therapies reduced the risk of SREs and prolonged the time to first SRE. The use of bonetargeted agents may also be associated with a survival benefit. Conclusion: BM are a common problem in advanced lung cancer. While the benefits of bone-targeted therapies have been demonstrated, their use is limited in non-trial populations. If better predictive markers of individual risk were available this might increase the appropriate use of bone-targeted agents. (C) 2012 Elsevier GmbH. All rights reserved.
引用
收藏
页码:22 / 29
页数:8
相关论文
共 67 条
[1]   Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis [J].
Ali, SM ;
Demers, LM ;
Leitzel, K ;
Harvey, HA ;
Clemens, D ;
Mallinak, N ;
Engle, L ;
Chinchilli, V ;
Costa, L ;
Brady, C ;
Seaman, J ;
Lipton, A .
ANNALS OF ONCOLOGY, 2004, 15 (03) :455-459
[2]  
[Anonymous], J CLIN ONCOLOGY OFFI
[3]  
[Anonymous], J CLIN ONCOLOGY OFFI
[4]  
[Anonymous], J CLIN ONCOLOGY OFFI
[5]  
[Anonymous], LUNG CANC AMSTERDAM
[6]  
[Anonymous], SUPPORTIVE CARE CANC
[7]   Update on the Systematic Review of Palliative Radiotherapy Trials for Bone Metastases [J].
Chow, E. ;
Zeng, L. ;
Salvo, N. ;
Dennis, K. ;
Tsao, M. ;
Lutz, S. .
CLINICAL ONCOLOGY, 2012, 24 (02) :112-124
[8]   Mechanisms and treatment of hypercalcemia of malignancy [J].
Clines, Gregory A. .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2011, 18 (06) :339-346
[9]   THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].
COLEMAN, RE ;
RUBENS, RD .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66
[10]   Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases Recommendations of a European Expert Panel [J].
De Marinis, Filippo ;
Eberhardt, Wilfried ;
Harper, Peter G. ;
Massuti Sureda, Bartomeu ;
Nackaerts, Kristiaan ;
Soerensen, Jens Benn ;
Syrigos, Kostas ;
Tredaniel, Jean .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (10) :1280-1288